LC3-associated phagocytosis and human diseases: Insights from mechanisms to therapeutic potential

FASEB J. 2024 Oct 31;38(20):e70130. doi: 10.1096/fj.202402126R.

Abstract

LC3-associated phagocytosis (LAP) is a distinct type of autophagy that involves the sequestration of extracellular material by phagocytes. Beyond the removal of dead cells and cellular debris from eukaryotic cells, LAP is also involved in the removal of a variety of pathogens, including bacteria, fungi, and viruses. These events are integral to multiple physiological and pathological processes, such as host defense, inflammation, and tissue homeostasis. Dysregulation of LAP has been associated with the pathogenesis of several human diseases, including infectious diseases, autoimmune diseases, and neurodegenerative diseases. Thus, understanding the molecular mechanisms underlying LAP and its involvement in human diseases may provide new insights into the development of novel therapeutic strategies for these conditions. In this review, we summarize and highlight the current consensus on the role of LAP and its biological functions in disease progression to propose new therapeutic strategies. Further studies are needed to illustrate the precise role of LAP in human disease and to determine new therapeutic targets for LAP-associated pathologies.

Keywords: LAP‐associated pathology; LC3‐associated phagocytosis; molecular mechanism; therapeutic strategy.

Publication types

  • Review

MeSH terms

  • Animals
  • Autoimmune Diseases / immunology
  • Autoimmune Diseases / metabolism
  • Autoimmune Diseases / therapy
  • Autophagy
  • Humans
  • Microtubule-Associated Proteins* / metabolism
  • Neurodegenerative Diseases / therapy
  • Phagocytosis*

Substances

  • Microtubule-Associated Proteins
  • MAP1LC3A protein, human